Next-gen therapeutics

The future of microbiome medicine

CONSORTIOME® is BiomeBank’s proprietary platform for next-generation microbial therapeutics. It builds complete, co-cultured gut communities that mirror the human microbiome, offering a scalable, precisely controlled alternative to donor-derived therapies. Guided by our bank of real-world clinical feedback, CONSORTIOME® delivers reproducible, high-quality interventions at scale, unlocking the next frontier in microbiome medicine.

Our team of translational microbiome experts have developed a breakthrough co-culturing platform that has enabled us to generate an artificial human gut microbial community in a bioreactor – the CONSORTIOME®

CONSORTIOME® is a rationally designed microbial consortia containing more than 90% of the known gene families that are found in a healthy person’s microbiome

WATCH: CEO and Co-founder Sam Costello explain BiomeBank’s revolutionary Consortiome Technology in more detail (2min)

This technological breakthrough is revolutionary for microbial therapies. With such a diverse range of gene families, the Consortiome® platform provides the ability to deliver therapies that have unprecedented, broad functional capability as well as highly targeted disease specific function. This provides the potential to improve efficacy compared to alternative microbiome therapies. In addition, the Consortiome® platform eliminates the reliance on stool donors and enables BiomeBank to produce microbial therapies at scale, to large markets, and at much lower cost than other microbial products.

Our first such co-cultured therapy, BB265, targeting Ulcerative Colitis and inflammatory bowel disease, has been designed using data from use of Biomictra® in discovery trials and will enter human trials in 2025.

Overlap of gene families between
healthy donors & BiomeBank’s Consortiome™

Annotation using the NCBI COG database (”Clusters of Orthologous Genes”) identified members of 1775 gene families from a healthy donor metagenome, of which over 90% of gene families were represented in the consortium metagenome.

Harnessing ecology and technology
to optimise the Drug Discovery Funnel

1.

IDENTIFY
Leveraging real-world, human data from our existing therapies to establish the causation of disease, our ‘human-first’ model of discovery allows us to more rapidly and precisely identify the ‘mechanism of action’ when compared to animal models.

2.

DEVELOP Harnessing the latest technology, we screen the real-world data and select candidate strains from our leading culture collection. Employing our cutting-edge Consortiome® platform we engineer an ecologically diverse consortia of microbes carrying that specific mechanism of action, as well as emergent therapeutic properties manifested within the whole community collectively.

3.

OPTIMISE
Delivering BiomeBank the highest potential drug candidates ready for clinical success.

The Development Pipeline

• BB265

BB265 is a rationally designed cultured microbiome therapy engineered for the treatment of ulcerative colitis. BB265 was developed using BiomeBank’s Consortiome platform and data from a discovery trial using Biomictra® (donor derived) therapy in patients with active ulcerative colitis. BB265 is scheduled to enter a phase 1b/2a study in 2025.

• BB128

BB128 is a rationally designed cultured microbiome therapy engineered for the treatment of an orphan disease indication. A discovery trial in this orphan disease indication is underway using Biomictra® .